SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains.

Appl Neuropsychol Adult

a New York University Langone Medical Center, Multiple Sclerosis Comprehensive Care Center, New York , New York , USA.

Published: February 2017

The objective of this study was to describe SymptoMScreen, an in-house developed tool for rapid assessment of MS symptom severity in routine clinical practice, and to validate SymptoMScreen against Performance Scales (PS). MS patients typically experience symptoms in many neurologic domains. A tool that would enable MS patients to efficiently relay their symptom severity across multiple domains to the healthcare providers could lead to improved symptom management. We developed "SymptoMScreen," a battery of 7-point Likert scales for 12 distinct domains commonly affected by MS: mobility, dexterity, body pain, sensation, bladder function, fatigue, vision, dizziness, cognition, depression, and anxiety. We administered SymptoMScreen and PS scales to consecutive MS patients at a specialty MS Care Center. We assessed the criterion and construct validity of SymptoMScreen by calculating Spearmen rank correlations between the SymptoMScreen composite score and PS composite score, and between SymptoMScreen subscale and the respective PS subscale scores, where applicable. A total of 410 patients with MS (age 46.6 ± 12.9 years; 74% female; mean disease duration 12.2 ± 8.7 years) completed the SymptoMScreen and PSs during their clinic visit. Composite SymptoMScreen score correlated strongly with combined PS score (r = 0.88, p < 0.0001). SymptoMScreen sub scores correlated strongly with the criterion measures of the respective PS (r = 0.69-0.87, p < 0.0001). Test-retest reliability of SymptoMScreen and its subscales was excellent (r = 0.71-0.94, p < .0001). SymptoMScreen is a single-page battery of Likert scales that assesses symptom impact in 12 domains commonly affected in MS. It has excellent criterion and construct validity. SymptoMScreen is patient and clinician friendly, takes approximately one minute to complete, and can help better document, understand, and manage patients' symptoms in routine clinical practice. SymptoMScreen is freely available to clinicians and researchers.

Download full-text PDF

Source
http://dx.doi.org/10.1080/23279095.2015.1125905DOI Listing

Publication Analysis

Top Keywords

symptom severity
12
symptomscreen
9
tool rapid
8
rapid assessment
8
assessment symptom
8
severity multiple
8
multiple domains
8
composite score
8
symptomscreen tool
4
symptom
4

Similar Publications

Background: Segmentation models for clinical data experience severe performance degradation when trained on a single client from one domain and distributed to other clients from different domain. Federated Learning (FL) provides a solution by enabling multi-party collaborative learning without compromising the confidentiality of clients' private data.

Methods: In this paper, we propose a cross-domain FL method for Weakly Supervised Semantic Segmentation (FL-W3S) of white blood cells in microscopic images.

View Article and Find Full Text PDF

Rationale: Gastric antral vascular ectasia (GAVE) is a rare acquired lesion characterized by vascular dilation in the gastric antrum, frequently results in occult or overt gastrointestinal bleeding. Endoscopic intervention remains the cornerstone of therapy. Argon plasma coagulation was previously considered a first treatment option.

View Article and Find Full Text PDF

Objective: Cognitive behavior therapy (CBT) is a well-established treatment for anxiety disorders in the general population. However, the efficacy of CBT for lesbian, gay, bisexual, transgender, queer, questioning, and otherwise non-heterosexual or non-cisgender (LGBTQ+) people with anxiety disorders is still emerging in the literature. This protocol proposes an exploratory, two-group, randomized controlled trial comparing the efficacy of CBT for anxiety disorders against a waitlist control group.

View Article and Find Full Text PDF

Rift Valley fever (RVF) is an important viral zoonotic disease that not only affects ruminants but causes serious morbidity and mortality in humans. In humans, its symptoms range from mild flu-like signs to a severe form such as retinal damage, meningoencephalitis to haemorrhagic fever. In this study, 202 human serum samples were collected from central and western parts of Zambia and tested for RVF-specific antibodies using a commercially available ELISA kit.

View Article and Find Full Text PDF

Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis of patients according to background chronic obstructive pulmonary disease (COPD) maintenance medication regimens.

Objective: This analysis aimed to explore the efficacy and safety of ensifentrine in patients receiving long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists with inhaled corticosteroids (LABA + ICS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!